Which hip treatment choice fits your life?

What can you try before a procedure?

Doing less for a few days is often the first move. Leg exercises can follow after sharp soreness settles. A cane may make each step easier when the hip is worse. These choices take effort, but they don't carry the same risks as a clinic procedure.

Pain medicine can help for a short time. It can also affect your stomach, kidneys, or heart. Don't borrow another person's pills or forget your regular medicines. Your doctor can tell you which medicine is safe and when to stop.

What are the non-surgical choices?

The catch is simple. A blood treatment isn't a sure fix. The letters PRP stand for platelet-rich plasma. A clinic spins a sample taken from you, then keeps its platelet-rich part.

QC Kinetix offers orthobiologics and biologic therapies, clinic terms for non-surgical treatments its medical providers make from your blood after examining you. They're blood-based regenerative treatments and hip surgery alternatives. They don't promise that surgery will never be needed. Ask which sore area may improve, what the visit involves, and how long you'll wait before judging the result.

When does surgery make more sense?

Surgery may fit when basic daily tasks stay hard. Soreness at rest and lost motion also matter. The X-ray must show wear in the same area that hurts during your exam. Surgery isn't a personal failure.

Hip replacement can help some people with severe joint damage. It still brings recovery time and surgical risk. Ask the surgeon how your health may change those risks. If you aren't ready, ask which exercises, medicines, or other non-surgical care still make sense.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programmes, tai chi, cane use and oral NSAIDs across hand, hip and knee OA - but its strong recommendations for topical NSAIDs and for intra-articular glucocorticoid injection are specific to the KNEE, not the hip.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. OARSI 2019 designates arthritis education plus structured land-based exercise as CORE treatments for hip OA, and explicitly states that intra-articular corticosteroids, intra-articular hyaluronic acid and aquatic exercise - Level 1B/2 treatments for KNEE OA - were NOT recommended for individuals with hip or polyarticular OA. Oral and transdermal opioids are strongly not recommended (Level 5).

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

3. The 2026 Cochrane update of exercise for hip osteoarthritis (18 trials, 1368 participants) found that against attention control or placebo, exercise may have little to no effect on pain (MD -6.31 points on 0-100, 95% CI -12.98 to 0.35, low certainty) and may improve physical function only slightly; against no treatment or usual care it probably reduces pain slightly (MD -7.19, 95% CI -10.70 to -3.68, moderate certainty) but the review states these improvements are unlikely to be clinically meaningful. This is a weaker result than the equivalent knee evidence and it must not be overstated.

   Hall M, et al. — Exercise for osteoarthritis of the hip.. Cochrane Database of Systematic Reviews, 2026. DOI: 10.1002/14651858.CD007912.pub3.

4. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

5. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.

   American Academy of Orthopaedic Surgeons — Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.. AAOS, 2017.

6. FDA states verbatim that regenerative medicine products including stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosomes have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders affecting blood production.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA, 2026.

7. A systematic review of five randomized trials of intra-articular PRP for hip OA (43-111 patients each) reported significant pain reduction and functional improvement in every included study with no major adverse events, but methodological quality ranged from low to high risk of bias and PRP preparation methods differed between studies - so this positive summary rests on a small and heterogeneous base and does not override the placebo-controlled network meta-analysis.

   Almutairi AN, Alazzeh MS — Efficacy and Safety of Platelet-Rich Plasma (PRP) Intra-articular Injections in Hip Osteoarthritis: A Systematic Review of Randomized Clinical Trials.. Cureus, 2024. DOI: 10.7759/cureus.72057.

8. Pooled analysis of national joint registries (Australia and Finland, 215,676 hip replacements) put 25-year all-cause construct survival at 57.9% (95% CI 57.1-58.7); pooled case series gave 77.6% (95% CI 76.0-79.2). The authors conclude patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

   Evans JT, et al. — How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up.. The Lancet, 2019. DOI: 10.1016/S0140-6736(18)31665-9.

9. A population-based analysis of 63,158 total hip replacements found 10-year implant survival of 95.6% and 20-year survival of 85.0%, but the LIFETIME risk of revision rose sharply with younger age at surgery - about 5% for those operated after 70, up to 35% (95% CI 30.9-39.1) for men in their early 50s, with a median time to revision of 4.4 years in those operated before 60.

   Bayliss LE, et al. — The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study.. The Lancet, 2017. DOI: 10.1016/S0140-6736(17)30059-4.